Literature DB >> 12957289

TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

James B Brugarolas1, Francisca Vazquez, Archana Reddy, William R Sellers, William G Kaelin.   

Abstract

Inactivation of the TSC2 tumor suppressor protein causes tuberous sclerosis complex (TSC), a disease characterized by highly vascular tumors. TSC2 has multiple functions including inhibition of mTOR (mammalian target of Rapamycin). We found that TSC2 regulates VEGF through mTOR-dependent and -independent pathways. TSC2 loss results in the accumulation of HIF-1alpha and increased expression of HIF-responsive genes including VEGF. Wild-type TSC2, but not a disease-associated TSC2 mutant, downregulates HIF. Rapamycin normalizes HIF levels in TSC2(-/-) cells, indicating that TSC2 regulates HIF by inhibiting mTOR. In contrast, Rapamycin only partially downregulates VEGF in this setting, implying an mTOR-independent link between TSC2 loss and VEGF. This pathway may involve chromatin remodeling since the HDAC inhibitor Trichostatin A downregulates VEGF in TSC2(-/-) cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12957289     DOI: 10.1016/s1535-6108(03)00187-9

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  201 in total

1.  TFEB, a novel mTORC1 effector implicated in lysosome biogenesis, endocytosis and autophagy.

Authors:  Samuel Peña-Llopis; James Brugarolas
Journal:  Cell Cycle       Date:  2011-12-01       Impact factor: 4.534

Review 2.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

3.  Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.

Authors:  Arnold S Kristof; Zhipeng You; Yin-Shan Han; Adel Giaid
Journal:  Peptides       Date:  2010-04-28       Impact factor: 3.750

4.  Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.

Authors:  C Lance Cowey; W Kimryn Rathmell
Journal:  Expert Opin Drug Discov       Date:  2008-03       Impact factor: 6.098

5.  p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis.

Authors:  Hilaire C Lam; Christian V Baglini; Alicia Llorente Lope; Andrey A Parkhitko; Heng-Jia Liu; Nicola Alesi; Izabela A Malinowska; Darius Ebrahimi-Fakhari; Afshin Saffari; Jane J Yu; Ana Pereira; Damir Khabibullin; Barbara Ogorek; Julie Nijmeh; Taylor Kavanagh; Adam Handen; Stephen Y Chan; John M Asara; William M Oldham; Maria T Diaz-Meco; Jorge Moscat; Mustafa Sahin; Carmen Priolo; Elizabeth P Henske
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

6.  Metastatic Renal Cancer: What Role for Everolimus?

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Clin Med Rev Oncol       Date:  2010-02-18

7.  The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex.

Authors:  Yilun Deng; Yuejuan Qin; Subramanya Srikantan; Anqi Luo; Zi-Ming Cheng; Shahida K Flores; Kris S Vogel; Exing Wang; Patricia L M Dahia
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

8.  Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.

Authors:  Brandon Faubert; Emma E Vincent; Takla Griss; Bozena Samborska; Said Izreig; Robert U Svensson; Orval A Mamer; Daina Avizonis; David B Shackelford; Reuben J Shaw; Russell G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

9.  Underactivation of the adiponectin-adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression.

Authors:  Nir Kleinmann; Wilhelmina C M Duivenvoorden; Sarah N Hopmans; Laura K Beatty; Shengjun Qiao; Daniel Gallino; Sarka Lhotak; Dean Daya; Athanasios Paschos; Richard C Austin; Jehonathan H Pinthus
Journal:  Clin Exp Metastasis       Date:  2013-10-05       Impact factor: 5.150

10.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Authors:  Ichiro Shiojima; Kaori Sato; Yasuhiro Izumiya; Stephan Schiekofer; Masahiro Ito; Ronglih Liao; Wilson S Colucci; Kenneth Walsh
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.